Ayala Pharmaceuticals, Inc. Quarterly Research and Development Expense in USD from Q2 2010 to Q4 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary: Ayala Pharmaceuticals, Inc. quarterly/annual Research and Development Expense history and growth rate from Q2 2010 to Q4 2023.
Ayala Pharmaceuticals, Inc. Research and Development Expense for the quarter ending December 31, 2023 was $5.41M, a 28.5% decline year-over-year.
Ayala Pharmaceuticals, Inc. Research and Development Expense for the twelve months ending December 31, 2023 was $24.1M, a 13.5% decline year-over-year.
Ayala Pharmaceuticals, Inc. annual Research and Development Expense for 2023 was $24.1M, a 13.5% decline from 2022.
Ayala Pharmaceuticals, Inc. annual Research and Development Expense for 2022 was $27.9M, a 164% increase from 2021.
Ayala Pharmaceuticals, Inc. annual Research and Development Expense for 2021 was $10.6M, a 32.3% decline from 2020.

Research and Development Expense, Trailing 12 Months (USD)

Research and Development Expense, Quarterly (USD)

Research and Development Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q4 2023	$24.1M	$5.41M	-$2.16M	-28.5%	Oct 1, 2023	Dec 31, 2023	10-K	2024-04-16
Q3 2023	$26.2M	$5.68M	-$1.52M	-21.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-20
Q2 2023	$27.8M	$5.72M	+$143K	+2.56%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-10
Q1 2023	$27.6M	$7.27M	-$238K	-3.17%	Jan 1, 2023	Mar 31, 2023	10-Q	2023-05-23
Q4 2022	$27.9M	$7.57M	+$5.92M	+358%	Oct 1, 2022	Dec 31, 2022	10-K	2024-04-16
Q3 2022	$21.9M	$7.2M	+$5.25M	+270%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-20
Q2 2022	$16.7M	$5.58M	+$3.88M	+228%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	$12.8M	$7.5M	+$3.16M	+72.7%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-23
Q4 2021	$9.65M	$1.65M	-$916K	-35.6%	Nov 1, 2021	Jan 31, 2022	10-Q	2022-03-17
Q3 2021	$10.6M	$1.95M	-$1.43M	-42.3%	Aug 1, 2021	Oct 31, 2021	10-K	2023-02-10
Q2 2021	$12M	$1.7M	-$1.76M	-50.8%	May 1, 2021	Jul 31, 2021	10-Q	2022-09-13
Q1 2021	$13.7M	$4.34M	+$422K	+10.8%	Feb 1, 2021	Apr 30, 2021	10-Q	2022-06-08
Q4 2020	$13.3M	$2.57M	-$2.29M	-47.1%	Nov 1, 2020	Jan 31, 2021	10-Q	2022-03-17
Q3 2020	$15.6M	$3.37M	-$3.57M	-51.4%	Aug 1, 2020	Oct 31, 2020	10-K	2022-02-14
Q2 2020	$19.2M	$3.46M	-$3.6M	-51%	May 1, 2020	Jul 31, 2020	10-Q	2021-09-10
Q1 2020	$22.8M	$3.92M	-$2.05M	-34.3%	Feb 1, 2020	Apr 30, 2020	10-Q	2021-06-14
Q4 2019	$24.8M	$4.86M	-$1.85M	-27.6%	Nov 1, 2019	Jan 31, 2020	10-Q	2021-03-16
Q3 2019	$26.7M	$6.94M	-$12.4M	-64%	Aug 1, 2019	Oct 31, 2019	10-K	2021-01-22
Q2 2019	$39M	$7.06M	-$3.5M	-33.1%	May 1, 2019	Jul 31, 2019	10-Q	2020-09-10
Q1 2019	$42.5M	$5.97M	-$4.4M	-42.4%	Feb 1, 2019	Apr 30, 2019	10-Q	2020-06-11
Q4 2018	$46.9M	$6.71M	-$10M	-60%	Nov 1, 2018	Jan 31, 2019	10-Q	2020-03-13
Q3 2018	$57M	$19.3M	-$3.47M	-15.2%	Aug 1, 2018	Oct 31, 2018	10-K	2019-12-20
Q2 2018	$60.4M	$10.6M	-$7.23M	-40.7%	May 1, 2018	Jul 31, 2018	10-Q	2019-09-09
Q1 2018	$67.7M	$10.4M	-$5.94M	-36.4%	Feb 1, 2018	Apr 30, 2018	10-Q	2019-06-10
Q4 2017	$73.6M	$16.8M	+$3.1M	+22.7%	Nov 1, 2017	Jan 31, 2018	10-Q	2019-03-12
Q3 2017	$70.5M	$22.8M	+$5.95M	+35.4%	Aug 1, 2017	Oct 31, 2017	10-K	2019-01-11
Q2 2017	$64.6M	$17.8M	+$7.65M	+75.4%	May 1, 2017	Jul 31, 2017	10-Q	2018-09-10
Q1 2017	$56.9M	$16.3M	+$7.55M	+86.2%	Feb 1, 2017	Apr 30, 2017	10-Q	2018-06-07
Q4 2016	$49.4M	$13.6M	+$584K	+4.47%	Nov 1, 2016	Jan 31, 2017	10-Q	2018-03-12
Q3 2016	$48.8M	$16.8M	+$9.52M	+131%	Aug 1, 2016	Oct 31, 2016	10-K	2017-12-21
Q2 2016	$39.3M	$10.1M	+$2.8M	+38.1%	May 1, 2016	Jul 31, 2016	10-Q	2017-09-11
Q1 2016	$36.5M	$8.76M	+$2.57M	+41.4%	Feb 1, 2016	Apr 30, 2016	10-Q	2017-06-06
Q4 2015	$33.9M	$13.1M	+$9.44M	+260%	Nov 1, 2015	Jan 31, 2016	10-Q	2017-03-10
Q3 2015	$24.5M	$7.29M	+$4.54M	+165%	Aug 1, 2015	Oct 31, 2015	10-K	2017-12-21
Q2 2015	$19.9M	$7.34M	+$4.34M	+144%	May 1, 2015	Jul 31, 2015	10-Q	2016-09-08
Q1 2015	$15.6M	$6.19M	+$4.65M	+301%	Feb 1, 2015	Apr 30, 2015	10-Q	2016-06-08
Q4 2014	$10.9M	$3.63M	+$2.07M	+133%	Nov 1, 2014	Jan 31, 2015	10-Q	2016-02-26
Q3 2014	$8.86M	$2.75M	+$1.54M	+127%	Aug 1, 2014	Oct 31, 2014	10-K	2017-01-09
Q2 2014	$7.32M	$3.01M	+$1.69M	+128%	May 1, 2014	Jul 31, 2014	10-Q	2015-09-11
Q1 2014	$5.63M	$1.54M	-$568K	-26.9%	Feb 1, 2014	Apr 30, 2014	10-Q	2015-06-15
Q4 2013	$6.2M	$1.56M	+$581K	+59.3%	Nov 1, 2013	Jan 31, 2014	10-Q	2015-03-13
Q3 2013	$5.62M	$1.21M	+$324K	+36.6%	Aug 1, 2013	Oct 31, 2013	10-K	2015-01-06
Q2 2013	$5.3M	$1.32M	-$11.5K	-0.86%	May 1, 2013	Jul 31, 2013	10-Q	2014-09-09
Q1 2013	$5.31M	$2.11M	-$103K	-4.65%	Feb 1, 2013	Apr 30, 2013	10-Q	2014-06-10
Q4 2012	$5.41M	$979K	-$1.23M	-55.8%	Nov 1, 2012	Jan 31, 2013	10-Q	2014-03-17
Q3 2012	$6.65M	$886K	-$800K	-47.5%	Aug 1, 2012	Oct 31, 2012	10-K	2014-01-29
Q2 2012	$7.45M	$1.33M	-$627K	-32%	May 1, 2012	Jul 31, 2012	10-Q	2013-09-16
Q1 2012	$8.07M	$2.22M	-$231K	-9.44%	Feb 1, 2012	Apr 30, 2012	10-Q	2013-06-14
Q4 2011	$8.3M	$2.21M	+$225K	+11.3%	Nov 1, 2011	Jan 31, 2012	10-Q/A	2013-03-25
Q3 2011	$8.08M	$1.69M			Aug 1, 2011	Oct 31, 2011	10-K/A	2013-02-14
Q2 2011		$1.96M	+$1.11M	+131%	May 1, 2011	Jul 31, 2011	10-Q/A	2012-10-04
Q1 2011		$2.45M			Feb 1, 2011	Apr 30, 2011	10-Q/A	2012-10-18
Q4 2010		$1.99M			Nov 1, 2010	Jan 31, 2011	10-Q/A	2012-10-18
Q2 2010		$848K			May 1, 2010	Jul 31, 2010	10-Q	2011-09-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.